Janux Therapeutics (JANX) Net Cash Flow (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Net Cash Flow data on file, last reported at -$506000.0 in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$506000.0, up 99.86% year-over-year; the trailing twelve-month figure through Mar 2026 was -$21.9 million (up 84.24% YoY), and the FY2025 annual result was -$378.3 million, down 191.95% from the prior year.
• Net Cash Flow declined to -$506000.0 in Q1 2026 per JANX's latest filing, from $3.9 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $403.9 million in Q4 2024 and troughed at -$356.9 million in Q1 2025.
• A 5-year average of $955647.1 and a median of $2.1 million in 2023 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 19571.26% in 2024 and fell as far as 6018.19% in 2024.
• A 5-year view of Net Cash Flow shows it stood at -$13.3 million in 2022, then soared by 115.41% to $2.1 million in 2023, then surged by 19571.26% to $403.9 million in 2024, then slumped by 99.02% to $3.9 million in 2025, then plunged by 112.83% to -$506000.0 in 2026.
• Business Quant data shows JANX's Net Cash Flow at -$506000.0 in Q1 2026, $3.9 million in Q4 2025, and -$4.1 million in Q3 2025.